File(s) stored somewhere else

Please note: Linked content is NOT stored on Singapore Institute of Technology and we can't guarantee its availability, quality, security or accept any liability.

Hypercoagulability, endotheliopathy, and inflammation approximating 1 year after recovery: Assessing the long-term outcomes in COVID-19 patients.

journal contribution
posted on 28.05.2022, 02:28 authored by Fan BE, Wong SW, Sum CLL, Lim GH, Pui Lam Bernard LeungPui Lam Bernard Leung, Tan CW, Ramanathan K, Dalan R, Cheung C, Lim XR, Sadasiv MS, Lye DC, Young BE, Yap ES, Chia YW, COVID-19 Clotting and Bleeding Investigators

Sustained hypercoagulability and endotheliopathy are present in convalescent COVID-19 patients for up to 4 months from recovery. The hemostatic, endothelial, and inflammatory profiles of 39 recovered COVID-19 patients were evaluated up to 16 months after recovery from COVID-19. These values were compared with a control group of healthy volunteers (n = 124). 39 patients (71.8% males, median age 43 years) were reviewed at a mean of 12.7 ± 3.6 months following recovery. One patient without cardiovascular risk factors had post COVID-19 acute ischaemic limb. Elevated D-dimer and Factor VIII levels above normal ranges were noted in 17.9% (7/39) and 48.7% (19/39) of patients respectively, with a higher median D-dimer 0.34 FEU μg/mL (IQR 0.28, 0.46) (p < .001) and Factor VIII 150% (IQR 171, 203) (p = .004), versus controls. Thrombin generation (Thromboscreen) showed a higher median endogenous thrombin potential (ETP) of 1352 nM*min (IQR 1152, 1490) (p = .002) and a higher median peak height of 221.4 nM (IQR 170.2, 280.4) (p = 0.01) and delayed lag time 2.4 min (1.42-2.97) (p = 0.0002) versus controls. Raised vWF:Ag and ICAM-1 levels were observed in 17.9% (7/39) and 7.7% (3/39) of patients respectively, with a higher median VWF:Ag 117% (IQR 86, 154) (p = 0.02) and ICAM-1 54.1 ng/mL (IQR 43.8, 64.1) (p = .004) than controls. IL-6 was noted to be raised in 35.9% (14/39) of patients, with a higher median IL-6 of 1.5 pg/mL (IQR 0.6, 3.0) (p = 0.004) versus controls. Subgroup analysis stratifying patients by COVID-19 severity and COVID-19 vaccination preceding SARS-CoV-2 infection did not show statistically significant differences. Hypercoagulability, endothelial dysfunction, and inflammation are still detectable in some patients approximately 1 year after recovery from COVID-19.

Funding

COVID19 CG008/National Healthcare Group-National Centre for Infectious Diseases (NHG-NCID) COVID-19 Centre Grant

History

Journal/Conference/Book title

American Journal of Hematology

Publication date

2022-04-28

Version

Published

Rights statement

Fan, B.E., S.W. Wong, C.L.L. Sum, G.H. Lim, B.P. Leung, C.W. Tan, K. Ramanathan, R. Dalan, C. Cheung, X.R. Lim, M.S. Sadasiv, D.C. Lye, B.E. Young, E.S. Yap, and Y.W. Chia. (2022) Hypercoagulability, endotheliopathy, and inflammation approximating 1 year after recovery: Assessing the long-term outcomes in COVID-19 patients. American journal of hematology, which has been published in final form at https://doi.org/10.1002/ajh.26575. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Use of Self-Archived Versions. This article may not be enhanced, enriched or otherwise transformed into a derivative work, without express permission from Wiley or by statutory rights under applicable legislation. Copyright notices must not be removed, obscured or modified. The article must be linked to Wiley’s version of record on Wiley Online Library and any embedding, framing or otherwise making available the article or pages thereof by third parties from platforms, services and websites other than Wiley Online Library must be prohibited.